Akebia Therapeutics (AKBA) Competitors $2.96 +0.16 (+5.71%) Closing price 04:00 PM EasternExtended Trading$2.96 +0.00 (+0.17%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. CRNX, KYMR, TLX, AMRX, NAMS, RARE, SRRK, XENE, VKTX, and MORShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Telix Pharmaceuticals (TLX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), Scholar Rock (SRRK), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Crinetics Pharmaceuticals Kymera Therapeutics Telix Pharmaceuticals Amneal Pharmaceuticals NewAmsterdam Pharma Ultragenyx Pharmaceutical Scholar Rock Xenon Pharmaceuticals Viking Therapeutics MorphoSys Akebia Therapeutics (NASDAQ:AKBA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Do analysts rate AKBA or CRNX? Akebia Therapeutics presently has a consensus price target of $6.75, suggesting a potential upside of 128.04%. Crinetics Pharmaceuticals has a consensus price target of $65.33, suggesting a potential upside of 84.14%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Akebia Therapeutics is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, AKBA or CRNX? Akebia Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Is AKBA or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Akebia Therapeutics' return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-17.91% N/A -13.47% Crinetics Pharmaceuticals N/A -32.28%-29.45% Do institutionals & insiders hold more shares of AKBA or CRNX? 33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AKBA or CRNX? In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 5 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.10 beat Crinetics Pharmaceuticals' score of 1.09 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, AKBA or CRNX? Akebia Therapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$203.73M3.85-$69.41M-$0.17-17.41Crinetics Pharmaceuticals$1.04M3,212.99-$298.41M-$4.11-8.63 SummaryAkebia Therapeutics beats Crinetics Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$784.83M$2.86B$5.81B$10.36BDividend YieldN/A59.99%5.86%4.62%P/E Ratio-17.4123.4276.8726.99Price / Sales3.85498.66449.2288.69Price / CashN/A169.8537.2260.63Price / Book-12.875.4313.836.37Net Income-$69.41M$32.95M$3.29B$271.46M7 Day Performance-1.00%0.85%0.94%2.34%1 Month Performance-4.82%6.06%5.31%7.77%1 Year Performance119.26%-0.87%84.25%31.08% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics3.8173 of 5 stars$2.96+5.7%$6.75+128.0%+104.4%$784.83M$203.73M-17.41430Positive NewsCRNXCrinetics Pharmaceuticals3.8822 of 5 stars$35.14-1.3%$68.86+96.0%-35.5%$3.31B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics1.9599 of 5 stars$43.26-0.6%$58.76+35.8%+1.7%$3.09B$47.07M-12.47170Trending NewsAnalyst ForecastInsider TradeGap UpTLXTelix Pharmaceuticals3.8173 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.06B$637.77M0.00N/AAnalyst ForecastHigh Trading VolumeAMRXAmneal Pharmaceuticals3.3856 of 5 stars$9.73+1.1%$11.60+19.2%+8.8%$3.06B$2.79B973.978,100Positive NewsAnalyst ForecastNAMSNewAmsterdam Pharma3.3061 of 5 stars$25.09-7.1%$41.55+65.6%+58.5%$3.04B$64.01M-15.494Positive NewsHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3147 of 5 stars$31.51-1.0%$81.50+158.6%-50.9%$3.04B$560.23M-5.701,294Positive NewsSRRKScholar Rock4.4684 of 5 stars$31.58+0.5%$45.75+44.9%+287.7%$3.04B$33.19M-10.85140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionXENEXenon Pharmaceuticals2.3981 of 5 stars$38.19-2.6%$53.30+39.6%-8.5%$2.94B$9.43M-10.76210Positive NewsOptions VolumeVKTXViking Therapeutics4.2722 of 5 stars$25.48-5.6%$86.92+241.1%-63.3%$2.86BN/A-16.6520MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies CRNX Alternatives KYMR Alternatives TLX Alternatives AMRX Alternatives NAMS Alternatives RARE Alternatives SRRK Alternatives XENE Alternatives VKTX Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe Return of The KingGold has just surpassed the euro to become the world’s #2 reserve asset — a milestone that signals a massive s...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
